
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc. demonstrated strong financial performance with a gross margin of 86.8%, reflecting a year-over-year increase of 160 basis points, surpassing the consensus estimate of 86.2%. The company also reported an increase in ordering facilities, rising to 1,138, indicating growth momentum in its operational reach. Moreover, potential upside drivers such as accelerated revenue growth from market share gains in the minimally invasive glaucoma surgery (MIGS) market, faster adoption of the TearCare system, and progress toward profitability contribute to a positive outlook for the company's future.
Bears say
The financial analysis indicates a negative outlook for Sight Sciences due to significant underperformance in the Dry Eye segment, which reported revenue of $0.3 million, missing consensus estimates of $0.4 million, and declining by 84% year-over-year. Additionally, the company’s decision to shift the TearCare product to reimbursed procedures has resulted in anticipated revenue decline and headwinds in future growth, as reflected in lowered GAAP EPS estimates for both 2025 and 2026. Furthermore, the recent implementation of Local Coverage Determinations (LCDs) negatively impacted the utilization of the OMNI Surgical System, contributing to the expectation of low- to mid-double-digit percentage revenue declines in the first quarter of 2025.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares